SEC Form SC 13G/A filed by Nuvation Bio Inc. (Amendment)
$NUVB
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/23/2025 | $6.00 | Mkt Outperform | Citizens JMP |
| 3/27/2024 | $1.40 → $10.00 | Hold → Buy | Jefferies |
| 3/26/2024 | $5.00 | Neutral → Buy | BTIG Research |
| 1/6/2023 | $5.00 → $2.00 | Buy → Hold | Jefferies |
| 8/2/2022 | $8.00 → $2.50 | Outperform → Market Perform | BMO Capital Markets |
| 8/2/2022 | Buy → Neutral | BTIG Research | |
| 5/4/2022 | $14.00 | Buy | H.C. Wainwright |
| 10/15/2021 | $16.00 | Buy | BTIG Research |
Citizens JMP initiated coverage of Nuvation Bio with a rating of Mkt Outperform and set a new price target of $6.00
Jefferies upgraded Nuvation Bio from Hold to Buy and set a new price target of $10.00 from $1.40 previously
BTIG Research upgraded Nuvation Bio from Neutral to Buy and set a new price target of $5.00
Received U.S. Food and Drug Administration (FDA) approval for IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) on June 11, 2025 Successfully started 70 patients on IBTROZI as of July 31, 2025, approximately seven weeks after U.S. FDA approval National Comprehensive Cancer Network® added taletrectinib (IBTROZI) as a Preferred Option to Clinical Practice Guidelines in Oncology for advanced ROS1+ NSCLC on June 20, 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $607.7 million as of June 30, 2025 Company to host a conference call today at 8:00 a.m. ET Nuvation Bio Inc. (
Presentations to include updated and additional Phase 2 clinical data for recently FDA-approved IBTROZI Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be presented at the IASLC 2025 World Conference on Lung Cancer (WCLC) taking place September 6–9, 2025 in Barcelona, Spain, and the European Society of Medical Oncology Congress Meeting (ESMO) October 17–21, 2025 in Berlin, Germany. These data include new results from the pivotal Phase 2 TRUST-I and TRUST-II studies on the efficacy and safety of IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanc
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (U.S. toll-free) and enter access code 926066. An archived recording will be available on Nuvation Bio's website for 90 days following the event.
10-Q - Nuvation Bio Inc. (0001811063) (Filer)
8-K - Nuvation Bio Inc. (0001811063) (Filer)
8-K - Nuvation Bio Inc. (0001811063) (Filer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
Received U.S. Food and Drug Administration (FDA) approval for IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) on June 11, 2025 Successfully started 70 patients on IBTROZI as of July 31, 2025, approximately seven weeks after U.S. FDA approval National Comprehensive Cancer Network® added taletrectinib (IBTROZI) as a Preferred Option to Clinical Practice Guidelines in Oncology for advanced ROS1+ NSCLC on June 20, 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $607.7 million as of June 30, 2025 Company to host a conference call today at 8:00 a.m. ET Nuvation Bio Inc. (
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (U.S. toll-free) and enter access code 926066. An archived recording will be available on Nuvation Bio's website for 90 days following the event.
Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high, durable response rates and brain-penetrant efficacy across different lines of therapy The safety and tolerability of IBTROZI have been well established in the pivotal program, with one of the largest safety datasets in ROS1+ NSCLC showing a favorable and consistent profile Company to host conference call tomorrow, June 12 at 7:30 a.m. EDT Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (
Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multicha
Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting First patient treated in a Phase 1/2 study of NUV-1511, the company's first drug-drug conjugate (DDC) to enter the clinic, for the treatment of various advanced solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024 Nuvation Bio Inc. (NYSE:NUVB), a late-stage
Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are t
SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)
SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)
SC 13D - Nuvation Bio Inc. (0001811063) (Subject)